目的 探讨男性人乳头瘤病毒（HPV）基因分型感染情况。方法 收集采用聚合酶链式反应反向斑点杂交法进行28种HPV基因分型检测的1 137例男性检查结果,进行回顾性分析。结果 1 137例男性患者中阳性441例,阳性率为38.79%,感染率居前5位的亚型依次为HPV6（11.35%）、HPV11（7.92%）、HPV16（5.10%）、HPV52（3.52%）、HPV43（2.64%）;就诊人群以20~39岁为主,感染人数也最多,各年龄组间阳性率比较差异无统计学意义（P>0.05）,≥50岁组HPV52型阳性率高于20~29岁组（P<0.05）和30~39岁组（P<0.05）。单一感染占67.35%,多重感染占32.65%,单一感染中低危型占比最多（41.27%）,多重感染中,二重感染占比最多（19.50%）,高低危混合感染为各种类型感染之首（15.87%）。结论 1 137例样本中HPV阳性率为38.79%,感染亚型以HPV6、HPV11、HPV16、HPV52、HPV43为主,单一低危型感染较为常见,各年龄组间阳性率相近。

Objective To investigate the genotypes of human papillomavirus（HPV）infection．Methods A total of 1 137 male patients’ diagnoses were collected and analyzed retrospectively,which came from the detections using polymerase chain reaction reverse dot blot hybridization to genotype 28 HPV．Results Among 1 137 male patients,441 were HPV positive,with a positive rate of 38.79%,the infections of top five HPV types were HPV6（11.35%）,HPV11（7.92%）,HPV16（5.10%）,HPV52（3.52%）,HPV43（2.64%）．The majority of the patients were the 20-39 age group,and the number of infections was also the highest．There was no statistical significance on the difference in the positive rate among different age groups（P>0.05）．The positive rate of HPV52 in ≥50 years old group was higher than the groups of aged 20~29（P<0.05）and 30~39（P<0.05）．The single and multiple infections accounted for 67.35% and 32.65%．The low-risk HPV accounted for the highest proportion（41.27%）in single infections,while in patients with multiple infections,the proportion of dual infections was the largest（19.50%）and the high- and low-risk HPV mixed infections was the maximum of the infection types（15.87%）．Conclusions The detection rate of positive HPV in 1 137 male patients was 38.79%,mainly were type 6,type 11,type 16,type 52 and type 43,and the single low-risk HPV infected was common．Positive rates were similar among different age groups．

目的 探讨CYP2C19不同基因分型对急性冠状动脉综合征(ACS)患者服用氯吡格雷后血小板聚集率的影响。方法 选取2015年1月—2016年3月入住心内科的ACS患者258例为研究对象。入院时及服用氯吡格雷三日后分别抽取静脉血检测血小板聚集率及CYP2C19基因型。结果 快代谢型组(extensive metabolisers, EM)和中代谢型组(intermediate metabolisers, IM)服药前后血小板最大聚集率分别为(58.76±15.45)% vs(35.17±10.26)%和(59.35±11.58)% vs(47.66±12.59)%(P<0.05), 而慢代谢型组(poor metabolisers, PM)的血小板最大聚集率无明显降低。快代谢型组的最大血小板聚集率的降低幅度比慢代谢型组大(23.58±12.39% vs 11.65±13.56%,P<0.05)。 共有33例(12.79%)患者为氯吡格雷抵抗, 其中快代谢型组中氯吡格雷抵抗者2例(1.67%), 中代谢型组中氯吡格雷抵抗者3例(2.80%), 慢代谢型组中氯吡格雷抵抗者28例(90.32%) (三组比较P=0.038)。结论 ACS患者CYP2C19基因分型与服用氯吡格雷后血小板最大聚集率有关,与氯吡格雷抵抗有关。

Objective To explore the relationship between platelet aggregation rate and CYP2C19 gene polymorphisms. Methods A total of 258 cases diagnosed as acute coronary syndrome (ACS) from January 2015 to March 2016. The platelet aggregation rate was tested before and 3 days after taking clopidogrel. CYP2C19 gene polymorphisms was tested by Gene chip hybridization technique. Results The platelet aggregation rate before and after taking clopidogrel was(58.76±15.45)% vs(35.17±10.26)% and(59.35±11.58)% vs(47.66±12.59)%(P<0.05)in EM group and IM group. But there was no change in PM group. The PM group were associated with a significant increase risk of clopidogrel resistance compared with EM group and IM group. Conclusion CYP2C19 gene polymorphisms influence the rate of platelet aggregation rate after taking clopidogrel and are associated with clopidogrel resistance in ACS patients.